2006 Competition Leads 
European Pharmaceutical Review
JUNE 24, 2022
This suggests that any of the modelled changes to the regulation could lead to a decrease in the number of OMPs developed… Some of the assessed changes to the regulation could undermine the business model under which OMP?focused Maarten has significant competition law experience in a variety of sectors. About the author. References.
PM360
SEPTEMBER 28, 2022
Chrys Kokino has been involved in the biosimilars market prior to the first biosimilar being approved in Europe in 2006. he is responsible for leading the commercialization efforts of specialty products which includes a broad portfolio of biosimilars. The level of competition is much greater today then we previously anticipated.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Brooks Group
FEBRUARY 23, 2009
The competition at this year's annual awards for sales and customer service once again featured some of America's top sales professionals and forward-thinking organizations. These nominations follow TBG's 2006 win as Consulting Sales Organization of the Year. The Brooks Group remains among the sales professional's elite companies.
The Brooks Group
FEBRUARY 23, 2009
The competition at this year's annual awards for sales and customer service once again featured some of America's top sales professionals and forward-thinking organizations. These nominations follow TBG's 2006 win as Consulting Sales Organization of the Year. The Brooks Group remains among the sales professional's elite companies.
European Pharmaceutical Review
JANUARY 31, 2025
Over 100 biosimilar medicines are approved for nearly 30 reference medicines, testimony to the rigour of the scientific standards leading to the European authorisation process. These reconsiderations lead the way to liberating untapped potential from biological standards of care. 6 billion in 2024 alone).
Pharmaceutical Technology
MARCH 24, 2023
Biosimilars are an important tool to facilitate competition, lower the price of drugs, and create savings across the board. Currently, 40 biosimilars are FDA-approved and 25 have launched, whereas the EMA has approved 86 biosimilars since 2006. Further, there remains scepticism on the efficacy and safety of biosimilars.
Healthcare Success
JULY 5, 2022
How to create marketing and lead generation systems that get results. Editor’s Note: I wrote the first version of this blog post back in 2006 when we launched Healthcare Success. Thus, marketing and lead acquisition costs can quickly spiral to the point of unprofitability. Lead Generation Best Practices.
Expert insights. Personalized for you.
105 
Let's personalize your content